Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria (NEUP) will present pharmacokinetic/pharmacodynamic analysis of its Phase 2b dataset for BNC210 at the ASCP 2025 Annual Meeting, with the analysis informing dose selection for a planned Phase 3 PTSD study. BNC210 is an oral, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor being developed for social anxiety disorder and PTSD. The company is also in partnership with Merck & Co., Inc.

Analysis

Neuphoria (NEUP) is set to present crucial pharmacokinetic/pharmacodynamic analysis from its BNC210 Attune Phase 2b dataset at the ASCP 2025 Annual Meeting on May 28th, 2025, a development carrying a strongly positive sentiment (overall score 0.6, NEUP-specific 0.8) and an optimistic tone. This presentation is significant as the analysis will directly inform dose selection for Neuphoria's planned Phase 3 study of BNC210 in post-traumatic stress disorder (PTSD). BNC210, the company's lead candidate, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, being developed for acute social anxiety disorder (SAD) and chronic PTSD. The company positions BNC210 as a novel, well-tolerated therapeutic offering rapid anxiety relief without common adverse effects such as sedation, cognitive impairment, or addiction. Furthermore, Neuphoria has an existing strategic partnership with Merck & Co., Inc. Despite the promising outlook, the announcement includes standard forward-looking statements, cautioning about the inherent uncertainties and risks in clinical development, including the progression of product candidates and reliance on collaborations.

Key Decisions for Investors

• Investors should closely monitor the outcomes of Neuphoria's presentation at the ASCP 2025 Annual Meeting, as the disclosed Phase 2b data and subsequent Phase 3 dose selection for BNC210 in PTSD represent a key near-term catalyst.
• Positive results enabling a clear path to a Phase 3 trial for BNC210 could significantly de-risk the asset and enhance Neuphoria's valuation, particularly given its first-in-class potential and favorable side-effect profile.
• While the strategic partnership with Merck offers validation, the clinical-stage nature of Neuphoria necessitates careful consideration of development risks and timelines, as highlighted by the company's forward-looking statements.